Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 3032950 in Moderate to Severe Ulcerative Colitis
NCT06636656Phase 2Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2024
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of BI 3032950 in ulcerative colitis (UC), sponsored by Boehringer Ingelheim. Started Dec 2024; status: recruiting.
02
Drugs
BI 3032950
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06636656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06636656.